目的：探讨利妥昔单抗联合CHOP方案治疗B细胞型非霍奇金淋巴瘤的临床效果和不良反应。方法选择96例CD20阳性的B细胞型非霍奇金淋巴瘤分为CHOP联合组和CHOP组,CHOP联合组采用利妥昔单抗与CHOP方案联合治疗,CHOP组只采用CHOP化疗方案。应用4个疗程后评价两组疗效及不良反应。结果 CHOP联合组治疗有效率为90.0％,高于CHOP组的72.4％,差异有统计学意义( P<0.05)。两组的不良反应率差异对比无统计学意义( P>0.05)。 CHOP联合组1年、3年、5年无进展生存率( PFS)为81.6％、61.2％、26.5％,总生存率( OS)为89.8％、65.3％、30.6％,均明显高于CHOP组,两组1年、3年、5年的PFS和OS比较差异有显著性( P<0.05)。结论采用利妥昔单抗与CHOP方案联合治疗B细胞型非霍奇金淋巴瘤,可以提高临床疗效和远期生存质量,且不因联合化疗而增加不良反应。%Objective To discuss the clinical effects and adverse reaction of rituximab combined with CHOP chemo￣therapy treating B￣cell non￣Hodgkin lymphoma. Methods 96 patients with CD20 positive B￣cell non￣Hodgkin lymphoma were chosen to divide into CHOP combination group and CHOP group.The patients in CHOP combination group were treated with rituximab combined with CHOP chemotherapy.The patients in CHOP group were treated with CHOP chemotherapy.The effects and adverse reaction in two groups were evaluated after 4 courses of treatment. Results The effective rate of CHOP combination group was 90.0% which was higher than 72.4% of CHOP group,the difference was statistically signifi￣cant (P<0.05).The difference of adverse reaction between two groups was not statistically significant (P>0.05).The pro￣gress free survival ( PFS) of CHOP combine group after 1 year,3 years,5years were 81.6%,61.2%,26.5% respectively,the overall survival (OS) were 89.8%,65.3%,30.6% respectively.The PFS and OS in CHOP combine group were obviously higher than CHOP group,and the differences of PFS and OS between two groups after 1 year,3 years,5years were statisti￣cally significant( P<0.05) . Conclusion The treatment of rituximab combined with CHOP chemotherapy for B￣cell non￣Hodgkin lymphoma could improve the clinical effects and the quality of long￣term survival,and it will not increase adverse reaction caused by combination chemotherapy.
展开▼
